Grail Shares Gain as FDA Panel Votes to Support Cancer Detection Test
By Elias SchisgallShares of Grail rose after the healthcare company said a U.S. regulatory committee voted to approve its Galleri multi-cancer early detection test.The stock was up 5.6% at $114.59 as of midday Thursday. Shares have risen 34% this year.The company on Wednesday said a panel on the Fo…